AMAG Pharmaceuticals, Inc. (AMAG)
-NasdaqGS 22.25 
0.31(1.41%) May 24, 4:00PM EDT
| Prev Close: | 21.94 |
|---|
| Open: | 21.89 |
|---|
| Bid: | 18.02 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 22.14 |
|---|
| Beta: | 0.27 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 21.76 - 22.35 |
|---|
| 52wk Range: | 13.38 - 25.67 |
|---|
| Volume: | 77,776 |
|---|
| Avg Vol (3m): | 139,142 |
|---|
| Market Cap: | 480.02M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.38 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 3 Horrendous Health-Care Stocks This Weekat Motley Fool(Sat 10:10AM EDT)
- AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a VEDGAR Online(Fri, May 24)
- A Review Of Upcoming Catalysts For Kidney Disease Biotech Players In 2013at Seeking Alpha(Fri, May 24)
- The Zacks Analyst Blog Highlights: AMAG Pharmaceuticals, Takeda Pharmaceutical, DISH Network, Sprint Nextel and Verizon CommunicationsZacks(Thu, May 23)
- Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc.PR Newswire(Wed, May 22)
- Swiss Issue for AMAG/Takeda's RiensoZacks(Wed, May 22)
- Amag slumps on Ferahame recall in SwitzerlandAP(Wed, May 22)
- Amag investigates anemia drug after report of death in Switzerlandat Reuters(Tue, May 21)
- Amag says anemia drug caused fatal reaction in Switzerlandat Reuters(Tue, May 21)
- AMAG says Takeda recalling one batch of Rienso from Swiss markettheflyonthewall.com(Tue, May 21)
- AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Other EventsEDGAR Online(Tue, May 21)
- Ferumoxytol Treatment Produced Significant Hemoglobin Increases in Adult Iron Deficiency Anemia Patients With Gastrointestinal Disease Who Had Failed or Could Not Tolerate Oral Iron TherapyGlobeNewswire(Tue, May 21)
- AMAG July Options Begin Tradingat Forbes(Mon, May 20)
- AMAG PHARMACEUTICALS INC. FinancialsEDGAR Online Financials(Fri, May 10)
- Ferumoxytol Results in Significant Hemoglobin Increases in Adult Iron Deficiency Anemia Patients With Abnormal Uterine Bleeding Who Had Failed or Could Not Tolerate Oral Iron TherapyGlobeNewswire(Mon, May 6)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 5.39 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.63 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.13 |
|---|
| Mean Recommendation*: | 2.4 |
|---|
| PEG Ratio (5 yr expected): | -0.49 |
|---|
Business Summary
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA).
View More